KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Shares Repurchased (2018 - 2025)

Sarepta Therapeutics has reported Shares Repurchased over the past 8 years, most recently at $114.1 million for Q4 2025.

  • For Q4 2025, Shares Repurchased fell 44.4% year-over-year to $114.1 million; the TTM value through Dec 2025 reached $218.6 million, down 38.41%, while the annual FY2025 figure was $139.1 million, 32.2% down from the prior year.
  • Shares Repurchased for Q4 2025 was $114.1 million at Sarepta Therapeutics, up from $16.4 million in the prior quarter.
  • Over five years, Shares Repurchased peaked at $205.1 million in Q4 2024 and troughed at -$136.7 million in Q4 2023.
  • A 5-year average of $46.0 million and a median of $45.9 million in 2024 define the central range for Shares Repurchased.
  • Biggest five-year swings in Shares Repurchased: surged 255.18% in 2022 and later tumbled 370.62% in 2023.
  • Year by year, Shares Repurchased stood at $29.8 million in 2021, then surged by 69.6% to $50.5 million in 2022, then tumbled by 370.62% to -$136.7 million in 2023, then soared by 250.07% to $205.1 million in 2024, then plummeted by 44.4% to $114.1 million in 2025.
  • Business Quant data shows Shares Repurchased for SRPT at $114.1 million in Q4 2025, $16.4 million in Q3 2025, and $41.6 million in Q2 2025.